AstraZeneca Pharmaceuticals LP Selects Ariba Enterprise Sourcing

24-Jan-2002

SUNNYVALE, Calif., January 22, 2002 -- Ariba®, Inc. a leading enterprise spend management solutions provider, announced that AstraZeneca, has selected Ariba® Enterprise Sourcing™ to assist with the company’s U.S initiative to streamline procurement processes.

AstraZeneca will use Ariba Enterprise Sourcing to standardize and improve its online sourcing processes across its business operations in the United States. Ariba Enterprise Sourcing will enable professional buyers at AstraZeneca to automate and manage the sourcing process, including locating suppliers, generating requests for quotations, and supporting the process of negotiating contract terms.

AstraZeneca has selected Accenture to help implement the Ariba Enterprise Sourcing solution over a twelve-week period with the initial rollout to include three pilot events. These pilot events will serve as a mechanism to help build electronic sourcing expertise specific to AstraZeneca’s processes and needs.

Ariba® Spend Management™ in Pharmaceuticals Many of the world’s leading pharmaceutical firms, including nine of the top ten pharmaceutical companies, rely on the Ariba Spend Management solutions to automate and streamline every step in the sourcing and procurement process, from spend analysis, to negotiation, to supplier selection, to payment.

With Ariba Spend Management, pharmaceutical buyers can coordinate collective purchases on a global basis across key divisions such as R&D, manufacturing and logistics, and sales and marketing, allowing them to capitalize on economies of scale to obtain lower prices. The increased visibility gained through the Ariba Spend Management solution also allows pharmaceutical companies to better identify trends, track spending, and make accurate forecasts for strategic planning. By automatically issuing notices that budget thresholds have been reached or exceeded and initiating appropriate workflows, the Ariba solution provides clear, immediate information on how much is being purchased—critical in enhancing overall spend management. These savings can then be invested in more strategic activities like researching promising new compounds or medical devices, handling FDA requirements, or launching new products.

https://www.bionity.com/en/news/7562/astrazeneca-pharmaceuticals-lp-selects-ariba-enterprise-sourcing.html